KREBSBIO61.00

Krebs Biochemicals and Industries Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersALPABALPHARMAVINEETLABNATCAPSUQBIOFILCHEMNECLIFEMANGALAMAAREYDRUGSMcap ₹132 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations50.443.323.725.2
Other Income0.50.72.02.2
Total Income50.944.025.827.4
Expenses
+ Cost of Materials Consumed5.42.50.10.0
+ Purchases of Stock-in-Trade0.10.00.00.5
+ Changes in Inventories1.13.00.3-0.0
+ Employee Benefit Expense16.516.610.410.4
+ Finance Costs4.75.97.17.3
+ Depreciation & Amortisation6.86.76.46.4
+ Other Expenses36.136.218.416.8
Total Expenses70.670.942.741.5
EBITDA-8.7-15.0-5.5-2.5
EBIT-15.5-21.7-11.9-8.9
Profit
PBT before Exceptional Items-19.7-26.9-16.9-14.1
Pretax Income-19.7-26.9-16.9-14.1
+ Current Tax0.00.00.00.0
Tax Expense0.00.00.00.0
Net Income-19.7-26.9-16.9-14.1
+ Net Income — Continuing Ops-19.7-26.9-16.9-14.1
+ Other Comprehensive Income-0.0-0.10.40.4
Total Comprehensive Income-19.8-27.0-16.5-13.7
Per Share
Basic EPS-9.16-12.49-7.85-6.54
Diluted EPS-9.16-12.49-7.85-6.54
Other Comprehensive Income — detail
+ Other Comprehensive Income-0.10.4
+ Items NOT to be Reclassified to P&L-0.0-0.10.4
Per Share — as-filed variants
Basic EPS — Continuing Operations-9.16-12.49-7.85-6.54
Diluted EPS — Continuing Operations-9.16-12.49-7.85-6.54
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit43.837.823.324.7
Gross Margin %86.9487.1798.3597.97
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)-19.7-26.9-16.9-14.1
Net Income Adj (tax-effected)-19.7-26.9-16.9-14.1
EPS Adj-9.16-12.49-7.85-6.54
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.00
Filed Debt Equity-0.02-0.01-0.010.00
Filed Dscr0.00-0.00-0.000.00
Filed Iscr-0.03-0.04-0.010.00
Paid Up Equity Capital21.621.621.621.6
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.